Sensitizing immune unresponsive colorectal cancers to immune checkpoint inhibitors through MAVS overexpression
Abstract
The majority of colorectal carcinomas (CRCs) are insensitive to programmed death protein-1/programmed death-ligand 1 (anti-PD-1/PD-L1) immune checkpoint inhibitor (ICI) antibodies. While there are many causes for ICI insensitivity, recent studies suggest that suppression of innate immune gene expression in tumor cells could be a root cause of this insensitivity and an important factor in the evolution of tumor immunosuppression.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Mar 01, 2022
- Source ID
- 10.1136/jitc-2021-003721
Entities
People
- Bin-jin Hwang
- Chaitanya Acharya
- Gangjun Lei
- Herbert Kim Lyerly
- Junping Wei
- Li-Chung Tsao
- Michael A. Morse
- Pankaj Agarwal
- Takuya Osada
- Tao Wang
- Timothy N. Trotter
- Xiao-yi Yang
- Zachary C Hartman
Organizations
- National Institutes of Health
- United States Department of Defense